Masatoshi Oya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masatoshi Oya has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Hiroya Kuroyanagi
Cancer Institute Hospital
4 shared publications - Masashi Ueno
Departments of Surgery, Cancer Institute Hospital
4 shared publications Tetsuichiro Muto
4 shared publicationsMeiki Fukuda
3 shared publicationsShinichi Sameshima
Department of Surgery, Dokkyo Medical University Koshigaya Hospital
3 shared publications- Takashi Okuyama
Department of Surgery, Dokkyo Medical University Koshigaya Hospital
3 shared publications
Latest Publications
- Open Access
- 1 January 2016
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 77 (5) , 1110-1115
A Case of Neuroendocrine Tumor of the Small Intestine Presented with an Abdominal Mass due to Lymph Node Metastasis
- 1 January 2016
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 77 (5) , 1110-1115
Open AccessA Case of Neuroendocrine Tumor of the Small Intestine Presented with an Abdominal Mass due to Lymph Node Metastasis
- 1 January 2016
- Published by Japan Society of Coloproctology in Nihon Daicho Komonbyo Gakkai Zasshi
- Vol. 69 (6) , 314-320
A Case of Undifferentiated Carcinoma of Rectosigmoid which Progressed Rapidly to its Termination
- 1 January 2016
- Published by Japan Society of Coloproctology in Nihon Daicho Komonbyo Gakkai Zasshi
- Vol. 69 (6) , 314-320
A Case of Undifferentiated Carcinoma of Rectosigmoid which Progressed Rapidly to its Termination
- 1 August 2014
- Vol. 41 (8) , 965-70
Efficacy of high-dose toremifene therapy in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors:a retrospective, single-institution study.
Aromatase inhibitors(AI)have established efficacy as first-line therapy in postmenopausal patients with hormone-sensitive metastatic breast cancer(MBC). However,the use of endocrine therapy has not yet been established for second-line and later therapy. Our study examined the efficacy of high-dose toremifene therapy(HD-TOR)in patients with MBC resistant to AIs. A retrospective analysis was carried out to determine outcomes in 85 postmenopausal patients with MBC resistant to AIs who began HD-TOR between May 2001 and October 2011. The patients received toremifene 120 mg once daily on consecutive days. The objective response rate(ORR)was 21.2%,the clinical benefit rate(CBR)was 41.2%,and the median time to treatment failure(TTF)was 7.3 months. The CBR was high in patients with ER-positive status(p=0.045),no visceral metastasis(p=0.037),HD -TOR as first- or second-line therapy(p=0.007),no history of tamoxifen(TAM)therapy(p=0.019),and no history of chemotherapy(p=0.017). Multivariate analysis showed that ER-positive status(p=0.005, odds ratio: 0.064)and no visceral metastasis(p=0.034, odds ratio: 0.323)were independent predictors of efficacy. The TTF was significantly longer in patients with ER-positive status(p=0.019)and no history of TAM therapy(p=0.015). Multivariate analysis showed that ER-positive status(p=0.025, hazard ratio: 0.377)and no history of TAM therapy(p=0.002, hazard ratio: 0.422)were independent predictors of efficacy. No patient discontinued HDTOR therapy due to adverse events. HD-TOR is an effective endocrine therapy for patients with MBC who have failed AIs.
- 1 August 2014
- Vol. 41 (8) , 965-70
Efficacy of high-dose toremifene therapy in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors:a retrospective, single-institution study.
Aromatase inhibitors(AI)have established efficacy as first-line therapy in postmenopausal patients with hormone-sensitive metastatic breast cancer(MBC). However,the use of endocrine therapy has not yet been established for second-line and later therapy. Our study examined the efficacy of high-dose toremifene therapy(HD-TOR)in patients with MBC resistant to AIs. A retrospective analysis was carried out to determine outcomes in 85 postmenopausal patients with MBC resistant to AIs who began HD-TOR between May 2001 and October 2011. The patients received toremifene 120 mg once daily on consecutive days. The objective response rate(ORR)was 21.2%,the clinical benefit rate(CBR)was 41.2%,and the median time to treatment failure(TTF)was 7.3 months. The CBR was high in patients with ER-positive status(p=0.045),no visceral metastasis(p=0.037),HD -TOR as first- or second-line therapy(p=0.007),no history of tamoxifen(TAM)therapy(p=0.019),and no history of chemotherapy(p=0.017). Multivariate analysis showed that ER-positive status(p=0.005, odds ratio: 0.064)and no visceral metastasis(p=0.034, odds ratio: 0.323)were independent predictors of efficacy. The TTF was significantly longer in patients with ER-positive status(p=0.019)and no history of TAM therapy(p=0.015). Multivariate analysis showed that ER-positive status(p=0.025, hazard ratio: 0.377)and no history of TAM therapy(p=0.002, hazard ratio: 0.422)were independent predictors of efficacy. No patient discontinued HDTOR therapy due to adverse events. HD-TOR is an effective endocrine therapy for patients with MBC who have failed AIs.
- 1 January 2014
- Published by Japan Society of Coloproctology in Nihon Daicho Komonbyo Gakkai Zasshi
- Vol. 67 (10) , 888-896
Preoperative Chemoradiotherapy for Advanced Rectal Cancer
- 1 January 2014
- Published by Japan Society of Coloproctology in Nihon Daicho Komonbyo Gakkai Zasshi
- Vol. 67 (10) , 888-896
Preoperative Chemoradiotherapy for Advanced Rectal Cancer
- 23 July 2009
- Vol. 56, 571-4
Laparoscopic rectal resection for primary rectal cancer combined with open upper major abdominal surgery: initial experience.
Although laparoscopy is accepted for treatment of colon cancer, its use for rectal cancer still has technical limitations. Whether a laparoscopic approach for rectal cancer is safe and beneficial remains unknown when simultaneous open upper major abdominal surgery is planned. Eight patients underwent laparoscopic rectal resection for primary rectal cancer combined with open upper major abdominal surgery. All laparoscopic rectal resections were successful, with no conversion to open surgery. Surgical procedures included two anterior, four low or super-low anterior, and two abdominoperineal resections. There were five simultaneous liver resections for suspected synchronous liver metastasis and three gastrectomies for advanced gastric cancer. Mean operating time was 517 (377-745) min, including 235 (165-330) min for rectal resection. Mean estimated blood loss was 398 (45-1200) mL, including 78 (0-550) mL for rectal resection. There was no postoperative morbidity. Overall morbidity was lower (0 vs. 47%) and time to flatus and liquid diet was faster (2.1 vs. 3.4 and 3.5 vs. 5.6 days, respectively) in the laparoscopic resection group compared with the open group with synchronous open upper major abdominal surgery. This preliminary report suggests that laparoscopic rectal resection for rectal cancer combined with open upper major abdominal surgery is a safe and feasible option in selected patients.
- 23 July 2009
- Vol. 56, 571-4
Laparoscopic rectal resection for primary rectal cancer combined with open upper major abdominal surgery: initial experience.
Although laparoscopy is accepted for treatment of colon cancer, its use for rectal cancer still has technical limitations. Whether a laparoscopic approach for rectal cancer is safe and beneficial remains unknown when simultaneous open upper major abdominal surgery is planned. Eight patients underwent laparoscopic rectal resection for primary rectal cancer combined with open upper major abdominal surgery. All laparoscopic rectal resections were successful, with no conversion to open surgery. Surgical procedures included two anterior, four low or super-low anterior, and two abdominoperineal resections. There were five simultaneous liver resections for suspected synchronous liver metastasis and three gastrectomies for advanced gastric cancer. Mean operating time was 517 (377-745) min, including 235 (165-330) min for rectal resection. Mean estimated blood loss was 398 (45-1200) mL, including 78 (0-550) mL for rectal resection. There was no postoperative morbidity. Overall morbidity was lower (0 vs. 47%) and time to flatus and liquid diet was faster (2.1 vs. 3.4 and 3.5 vs. 5.6 days, respectively) in the laparoscopic resection group compared with the open group with synchronous open upper major abdominal surgery. This preliminary report suggests that laparoscopic rectal resection for rectal cancer combined with open upper major abdominal surgery is a safe and feasible option in selected patients.
- 8 July 2009
- Vol. 56 (90) , 378-80
Laparoscopic assisted intersphincteric resection following preoperative chemoradiation therapy for locally advanced lower rectal cancer: report of a case.
Laparoscopy-assisted surgery for rectal surgery has been shown to be both technically feasible and a safe alternative to laparotomy. It can be combined with preoperative chemoradiation and sphincter preserving operation for advanced low rectal cancer. We report a case of advanced lower rectal cancer, which was treated with laparoscopy-assisted total mesorectal excision and intersphincteric resection (abdomino-anal resection with coloanal anastomosis) following preoperative chemoradiation. In this patient, preoperative chemoradiation was very effective and no cancer cells remained in resected specimens.
- 8 July 2009
- Vol. 56 (90) , 378-80
Laparoscopic assisted intersphincteric resection following preoperative chemoradiation therapy for locally advanced lower rectal cancer: report of a case.
Laparoscopy-assisted surgery for rectal surgery has been shown to be both technically feasible and a safe alternative to laparotomy. It can be combined with preoperative chemoradiation and sphincter preserving operation for advanced low rectal cancer. We report a case of advanced lower rectal cancer, which was treated with laparoscopy-assisted total mesorectal excision and intersphincteric resection (abdomino-anal resection with coloanal anastomosis) following preoperative chemoradiation. In this patient, preoperative chemoradiation was very effective and no cancer cells remained in resected specimens.
- 7 July 2009
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 13 (9) , 1614-1618
Short-Term Outcomes of Laparoscopic Rectal Surgery for Primary Rectal Cancer in Elderly Patients: Is it Safe and Beneficial?
- 7 July 2009
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 13 (9) , 1614-1618
Short-Term Outcomes of Laparoscopic Rectal Surgery for Primary Rectal Cancer in Elderly Patients: Is it Safe and Beneficial?
- 18 May 2009
- Published by Wiley in Colorectal Disease
- Vol. 11 (5) , 464-469
Comparison of preoperative whole‐body positron emission tomography with MDCT in patients with primary colorectal cancer
Objective Preoperative use of emission tomography with18F‐fluorodeoxyglucose (FDG‐PET) in patients with primary colorectal cancer remains controversial. This study evaluated the additional value of FDG‐PET in comparison with routine multidetector row computed tomography (MDCT) in patients with primary colorectal cancer.Method Retrospective analysis was performed in 65 patients with colorectal cancer who underwent whole‐body FDG‐PET. Results of FDG‐PET were compared with routine preoperative evaluation by MDCT regarding detection of primary tumour, lymph node involvement and distant metastases. All images were evaluated before surgery.Results Tumour detection rate was 100% (63/63) for MDCT and 98% (62/63) for FDG‐PET. Lymph node involvement was pathologically confirmed in 35 patients. MDCT and FDG‐PET displayed sensitivities of 89% (31/35; 95% CI: 73–97%) and 43% (15/35; 95% CI: 26–61%) and specificities of 52% (11/21; 95% CI: 30–74%) and 95% (20/21; 95% CI: 76–100%), respectively. Liver metastases were present in 22 patients. MDCT and FDG‐PET showed accuracies of 98% (64/65; 95% CI: 92–100%) and 97% (63/65; 95% CI: 89–100%), respectively. FDG‐PET detected additional extrahepatic metastatic lesions and affected treatment plan compared with MDCT in 10 patients.Conclusion Preoperative FDG‐PET is not superior to MDCT for detection of primary tumour, lymph node involvement or liver metastases, but may have potential clinical value in patients with advanced colorectal cancer by detecting extrahepatic distant metastases.
- 18 May 2009
- Published by Wiley in Colorectal Disease
- Vol. 11 (5) , 464-469
Comparison of preoperative whole‐body positron emission tomography with MDCT in patients with primary colorectal cancer
Objective Preoperative use of emission tomography with18F‐fluorodeoxyglucose (FDG‐PET) in patients with primary colorectal cancer remains controversial. This study evaluated the additional value of FDG‐PET in comparison with routine multidetector row computed tomography (MDCT) in patients with primary colorectal cancer.Method Retrospective analysis was performed in 65 patients with colorectal cancer who underwent whole‐body FDG‐PET. Results of FDG‐PET were compared with routine preoperative evaluation by MDCT regarding detection of primary tumour, lymph node involvement and distant metastases. All images were evaluated before surgery.Results Tumour detection rate was 100% (63/63) for MDCT and 98% (62/63) for FDG‐PET. Lymph node involvement was pathologically confirmed in 35 patients. MDCT and FDG‐PET displayed sensitivities of 89% (31/35; 95% CI: 73–97%) and 43% (15/35; 95% CI: 26–61%) and specificities of 52% (11/21; 95% CI: 30–74%) and 95% (20/21; 95% CI: 76–100%), respectively. Liver metastases were present in 22 patients. MDCT and FDG‐PET showed accuracies of 98% (64/65; 95% CI: 92–100%) and 97% (63/65; 95% CI: 89–100%), respectively. FDG‐PET detected additional extrahepatic metastatic lesions and affected treatment plan compared with MDCT in 10 patients.Conclusion Preoperative FDG‐PET is not superior to MDCT for detection of primary tumour, lymph node involvement or liver metastases, but may have potential clinical value in patients with advanced colorectal cancer by detecting extrahepatic distant metastases.
- 15 November 2008
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 13 (3) , 521-525
Safety of Laparoscopic Total Mesorectal Excision for Low Rectal Cancer with Preoperative Chemoradiation Therapy
- 15 November 2008
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 13 (3) , 521-525
Safety of Laparoscopic Total Mesorectal Excision for Low Rectal Cancer with Preoperative Chemoradiation Therapy
- Open Access
- 1 January 2008
- Published by Japan Society of Coloproctology in Nihon Daicho Komonbyo Gakkai Zasshi
- Vol. 61 (10) , 981-986
Endoscopic Diagnosis of Anal Canal Cancer
肛門管癌は,体表に近いにもかかわらず進行癌で発見されるものが多い.その理由は,羞恥心から来院が遅れること,確定診断が遅れることなどが主な原因と考えられる.頻度はそれほど高くはないが,過去3年間に当院で経験した直腸癌380例中肛門管癌は12例(3.2%)で,進行癌が8例,早期癌4例であった.内視鏡診断は,肛門部を注意して観察することで早期診断可能であるが,反転観察が重要である.通常の観察では肛門管は接線方向の観察になり病変部の正面視は不可能である.反転しスコープ軸を回転させることで肛門管の観察は可能となる.さらに,色素撒布と拡大観察を加える腫瘍ピットを観察することで腺癌の診断が可能となる.さらに,NBIを用いた拡大観察を行うことで扁平上皮癌の診断が可能である.すなわち,食道のdysplasiaや癌でみられるものと同様の血管パターンが観察されることから診断可能である.
- 1 January 2008
- Published by Japan Society of Coloproctology in Nihon Daicho Komonbyo Gakkai Zasshi
- Vol. 61 (10) , 981-986
Open AccessEndoscopic Diagnosis of Anal Canal Cancer
肛門管癌は,体表に近いにもかかわらず進行癌で発見されるものが多い.その理由は,羞恥心から来院が遅れること,確定診断が遅れることなどが主な原因と考えられる.頻度はそれほど高くはないが,過去3年間に当院で経験した直腸癌380例中肛門管癌は12例(3.2%)で,進行癌が8例,早期癌4例であった.内視鏡診断は,肛門部を注意して観察することで早期診断可能であるが,反転観察が重要である.通常の観察では肛門管は接線方向の観察になり病変部の正面視は不可能である.反転しスコープ軸を回転させることで肛門管の観察は可能となる.さらに,色素撒布と拡大観察を加える腫瘍ピットを観察することで腺癌の診断が可能となる.さらに,NBIを用いた拡大観察を行うことで扁平上皮癌の診断が可能である.すなわち,食道のdysplasiaや癌でみられるものと同様の血管パターンが観察されることから診断可能である.